{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:58:00Z","timestamp":1781326680808,"version":"3.54.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013209","name":"Hellenic Foundation for Research and Innovation","doi-asserted-by":"publisher","award":["18603"],"award-info":[{"award-number":["18603"]}],"id":[{"id":"10.13039\/501100013209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118436","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T15:57:14Z","timestamp":1764431834000},"page":"118436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Thiazolyl 4-carboxylate ketone as a new warhead for a highly potent SARS-CoV-2 main protease inhibitor"],"prefix":"10.1016","volume":"303","author":[{"given":"Maria A.","family":"Theodoropoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"El Kilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Mantzourani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Jochmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"R\u00f6ske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroula G.","family":"Kokotou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hilgenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3753-7082","authenticated-orcid":false,"given":"George","family":"Kokotos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118436_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118436_bib2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118436_bib3","unstructured":"Coronavirus Disease (COVID-19) \u2013 World Health Organization, (n.d.). https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (accessed September 21, 2024)."},{"key":"10.1016\/j.ejmech.2025.118436_bib4","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1021\/acsinfecdis.1c00237","article-title":"Recognition of divergent viral substrates by the SARS-CoV-2 main protease","volume":"7","author":"MacDonald","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118436_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118436_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (Mpro): structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2025.118436_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118436_bib8","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.3390\/molecules27082523","article-title":"Advances in the development of SARS-CoV-2 Mpro inhibitors","volume":"27","author":"Agost-Beltr\u00e1n","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118436_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115772","article-title":"Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: a comprehensive review","volume":"260","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107380","article-title":"Non-peptidic inhibitors targeting SARS-CoV-2 main protease: a review","volume":"147","author":"Xiao","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116704","article-title":"Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: insights into their design, classification, biological activity, and binding interactions","volume":"277","author":"Shawky","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib12","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118436_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118436_bib14","first-page":"100835","article-title":"Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial, Lancet Reg","volume":"38","author":"Wang","year":"2023","journal-title":"Health West. Pac."},{"key":"10.1016\/j.ejmech.2025.118436_bib15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate Covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118436_bib16","doi-asserted-by":"crossref","first-page":"106339","DOI":"10.1016\/j.jinf.2024.106339","article-title":"Real-world effectiveness and safety of simnotrelvir\/ritonavir for COVID-19: a nationwide, multicenter, prospective, observational cohort study in China","volume":"89","author":"Han","year":"2024","journal-title":"J. Infect."},{"key":"10.1016\/j.ejmech.2025.118436_bib17","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118436_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40265-024-02039-y","article-title":"Ensitrelvir fumaric acid: first approval","volume":"84","author":"Syed","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118436_bib19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug\u2013drug interactions between the COVID-19 antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118436_bib20","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejmech.2025.118436_bib21","doi-asserted-by":"crossref","first-page":"11656","DOI":"10.1021\/acs.jmedchem.4c01342","article-title":"Fixing the achilles heel of Pfizer\u2019s Paxlovid for COVID-19 treatment","volume":"67","author":"Brewitz","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib22","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1021\/jacsau.4c00508","article-title":"A structural comparison of oral SARS-CoV-2 drug candidate ibuzatrelvir complexed with the main protease (Mpro) of SARS-CoV-2 and MERS-CoV","volume":"4","author":"Chen","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.ejmech.2025.118436_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.118436_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02815-22","article-title":"The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to Nirmatrelvir","volume":"14","author":"Jochmans","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2025.118436_bib25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to Nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2025.118436_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/acsbiomedchemau.4c00045","article-title":"An investigation of Nirmatrelvir (Paxlovid) resistance in SARS-CoV-2 Mpro","volume":"4","author":"Yaghi","year":"2024","journal-title":"ACS Bio Med Chem Au"},{"key":"10.1016\/j.ejmech.2025.118436_bib27","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1021\/acs.jmedchem.1c00665","article-title":"3CL protease inhibitors with an electrophilic arylketone moiety as anti-SARS-CoV-2 agents","volume":"65","author":"Konno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib28","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1021\/jm500192s","article-title":"Inhibition of Group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo","volume":"57","author":"Kokotos","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41467-024-55536-9","article-title":"Next generation thiazolyl ketone inhibitors of cytosolic phospholipase A2 \u03b1 for targeted cancer therapy","volume":"16","author":"Ashcroft","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118436_bib30","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.bmc.2007.11.015","article-title":"Inhibitors of proteases and amide hydrolases that employ an \u03b1-ketoheterocycle as a key enabling functionality","volume":"16","author":"Maryanoff","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib31","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2174\/156802606777951064","article-title":"Peptidyl fluoro-ketones as proteolytic enzyme inhibitors","volume":"6","author":"Sani","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0960-894X(99)00587-9","article-title":"Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors","volume":"10","author":"Dragovich","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118436_bib33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/ml3000534","article-title":"Design and synthesis of potent, selective inhibitors of matriptase","volume":"3","author":"Colombo","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118436_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejmech.2017.02.006","article-title":"Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids","volume":"129","author":"St-Georges","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib35","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.bmcl.2009.03.118","article-title":"New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors","volume":"19","author":"Regnier","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118436_bib36","doi-asserted-by":"crossref","first-page":"12290","DOI":"10.1021\/acs.jmedchem.0c00530","article-title":"Amide bond bioisosteres: strategies, synthesis, and successes","volume":"63","author":"Kumari","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.jmedchem.7b01430","article-title":"Discovery of peptidomimetic antibody\u2013drug conjugate linkers with enhanced protease specificity","volume":"61","author":"Wei","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib38","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1021\/ol701581g","article-title":"An efficient, inexpensive, and shelf-stable diazotransfer reagent: Imidazole-1-sulfonyl azide hydrochloride","volume":"9","author":"Goddard-Borger","year":"2007","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.118436_bib39","doi-asserted-by":"crossref","first-page":"14787","DOI":"10.1021\/acs.jmedchem.3c01385","article-title":"Development of first-in-class dual Sirt2\/HDAC6 inhibitors as molecular tools for dual inhibition of tubulin deacetylation","volume":"66","author":"Sinatra","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib40","doi-asserted-by":"crossref","first-page":"13686","DOI":"10.1039\/D1SC03628A","article-title":"Discovery of SARS-CoV-2 Mpro peptide inhibitors from modelling substrate and ligand binding","volume":"12","author":"Chan","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2025.118436_bib41","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1021\/acschembio.4c00096","article-title":"High-resolution substrate specificity profiling of SARS-CoV-2 Mpro; comparison to SARS-CoV Mpro","volume":"19","author":"Yaghi","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118436_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.medj.2023.12.004","article-title":"Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19","volume":"5","author":"Mao","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2025.118436_bib43","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1021\/acs.jmedchem.3c02351","article-title":"Structural elucidation and antiviral activity of covalent cathepsin L inhibitors","volume":"67","author":"Falke","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib44","doi-asserted-by":"crossref","first-page":"21035","DOI":"10.1021\/jacs.2c04626","article-title":"Dual inhibitors of main protease (Mpro) and cathepsin L as potent antivirals against SARS-CoV2","volume":"144","author":"Mondal","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118436_bib45","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/acsmedchemlett.3c00562","article-title":"Identification of dual inhibitors targeting main protease (Mpro) and cathepsin L as potential anti-SARS-CoV-2 agents","volume":"15","author":"Previti","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118436_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.118436_bib47","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/jacs.4c11620","article-title":"Dual inhibitors of SARS-CoV-2 3CL protease and human cathepsin L containing glutamine isosteres are anti-CoV-2 agents","volume":"147","author":"Kumar","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118436_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118436_bib49","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118436_bib50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118436_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108299","article-title":"Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4\/5 on spike function and neutralization","volume":"26","author":"Pastorio","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.118436_bib52","author":"Peacock"},{"key":"10.1016\/j.ejmech.2025.118436_bib53","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1021\/acs.jmedchem.4c02172","article-title":"Structure-based optimization of pyridone \u03b1-ketoamides as inhibitors of the SARS-CoV-2 main protease","volume":"68","author":"Akula","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib54","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.1021\/acs.jmedchem.2c01131","article-title":"Diastereomeric resolution yields highly potent inhibitor of SARS-CoV-2 main protease","volume":"65","author":"Cooper","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc5332","article-title":"3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV\u2013infected mice","volume":"12","author":"Rathnayake","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118436_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115376","article-title":"Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV)","volume":"254","author":"Dampalla","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib57","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib58","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41467-021-22362-2","article-title":"Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Iketani","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118436_bib59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41467-021-20900-6","article-title":"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"12","author":"Hattori","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118436_bib60","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and structural insights about potential SARS-CoV-2 evasion of Nirmatrelvir","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib61","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1021\/acs.jmedchem.2c01627","article-title":"Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic cysteine","volume":"66","author":"Brewitz","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118436_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2025.118436_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118436_bib64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1107\/S0907444909042589","article-title":"Molecular replacement with MOLREP","volume":"66","author":"Vagin","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118436_bib65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118436_bib66","author":"Schr\u00f6dinger"},{"key":"10.1016\/j.ejmech.2025.118436_bib67","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1038\/s41467-020-19684-y","article-title":"STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters","volume":"11","author":"Boudewijns","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118436_bib68","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jviromet.2012.04.011","article-title":"A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE","volume":"183","author":"Jochmans","year":"2012","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ejmech.2025.118436_bib69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1107\/S0021889897003907","article-title":"On the use of the merging R factor as a quality indicator for X-ray data","volume":"30","author":"Weiss","year":"1997","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118436_bib70","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1126\/science.1218231","article-title":"Linking crystallographic model and data quality","volume":"336","author":"Karplus","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118436_bib71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118436_bib72","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1021\/acsomega.8b01214","article-title":"Highly potent 2-oxoester inhibitors of cytosolic phospholipase A2 (GIVA cPLA2)","volume":"3","author":"Psarra","year":"2018","journal-title":"ACS Omega"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:41:44Z","timestamp":1781325704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":72,"alternative-id":["S0223523425012012"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118436","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thiazolyl 4-carboxylate ketone as a new warhead for a highly potent SARS-CoV-2 main protease inhibitor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118436"}}